BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, ADCs , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies
MilliporeSigma, a life science leader, is a business of Merck KGaA, Darmstadt, Germany, providing services as a strategic partner to help advance the promise of life saving therapies. With the acquisition of Sigma-Aldrich (SAFC), we now have the largest offering of products and contract manufacturing services for formulations, actives and biotechnology processes. Our joint ADC offering now includes a full range of services that spans conjugation, mAbs, linkers and payloads, process development, and much more
Morphotek®is a biotechnology company focused on the development of antibody-based therapies. In oncology, we are developing biological therapies that target underlying disease pathways and can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies. As part of this approach, we have developed proprietary ADC technologies that utilize REsidue-SPEcific Conjugation Technology™ (RESPECT™) and proprietary payloads to develop ADCs to internal and clients’ strategic targets through our end-to-end ADC Services
Piramal Pharma Solution’s Antibody Drug Conjugate Business is one of the world’s leading contract development and manufacturing sites delivering early and late phase clinical and commercial supplies. Our flexible manufacturing regime and dedication to ADC processing is why our clients choose Piramal as their preferred partner. We seek to reduce the complexity associated with ADC processing allowing for integrated and seamless scale-up of each unique ADC program, including fill finish.
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Utilizing our technology, we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies.
NewBio Therapeutics (NewBio) is an innovative company focusing on the discovery of proprietary site-specific conjugation technology, toxins and antibody-drug conjugates (ADCs) for cancer treatment. Our site-specific linkers lead to the preparation of more homogeneous ADC products with controlled DAR values of four, three, or two, which bear improved in-vivo stability, lower toxicity, and enhanced anti-cancer activities. While building up our own ADC pipelines, we are also seeking worldwide collaborations with other corporations.
Novasep is a leading provider of integrated manufacturing solutions for the Life Science industries offering a wide range of flexible assets, specialized technologies and advanced process capabilities for the synthesis and purification of APIs and HPAPIs. We provide unique services for the development and cGMP manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody.